Mohit Bansal
Stock Analyst at Wells Fargo
(4.23)
# 339
Out of 5,182 analysts
200
Total ratings
66.38%
Success rate
9.55%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Upgrades: Overweight | $200 → $250 | $188.37 | +32.72% | 17 | Apr 20, 2026 | |
| MRK Merck & Co. | Maintains: Overweight | $135 → $150 | $114.58 | +30.91% | 14 | Mar 12, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $235 → $250 | $200.89 | +24.45% | 4 | Feb 25, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $65 → $75 | $67.85 | +10.55% | 8 | Feb 19, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $325 → $375 | $349.50 | +7.30% | 13 | Feb 19, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $70 → $75 | $53.89 | +39.17% | 7 | Feb 18, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $175 | $131.07 | +33.52% | 8 | Feb 13, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $150 → $165 | $133.77 | +23.35% | 14 | Feb 11, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $55 → $60 | $59.06 | +1.59% | 11 | Feb 6, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,200 → $1,280 | $913.87 | +40.06% | 19 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $745 → $800 | $760.98 | +5.13% | 22 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $5 | $4.00 | +25.00% | 6 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $1.93 | +314.51% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $515 | $439.86 | +17.08% | 12 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $28.34 | +94.07% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $200.88 | +29.43% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $40.45 | -13.47% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $106.68 | +40.61% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $55.75 | -15.70% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $22.82 | +31.46% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $38.30 | +82.77% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.48 | +13.29% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $29.55 | +6,245.18% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $8.00 | +350.00% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $7.63 | +149.02% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.53 | +3,821.57% | 4 | Dec 3, 2019 |
Biogen
Apr 20, 2026
Upgrades: Overweight
Price Target: $200 → $250
Current: $188.37
Upside: +32.72%
Merck & Co.
Mar 12, 2026
Maintains: Overweight
Price Target: $135 → $150
Current: $114.58
Upside: +30.91%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $235 → $250
Current: $200.89
Upside: +24.45%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $65 → $75
Current: $67.85
Upside: +10.55%
Amgen
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $325 → $375
Current: $349.50
Upside: +7.30%
BioMarin Pharmaceutical
Feb 18, 2026
Maintains: Overweight
Price Target: $70 → $75
Current: $53.89
Upside: +39.17%
Neurocrine Biosciences
Feb 13, 2026
Maintains: Overweight
Price Target: $180 → $175
Current: $131.07
Upside: +33.52%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $150 → $165
Current: $133.77
Upside: +23.35%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $55 → $60
Current: $59.06
Upside: +1.59%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,200 → $1,280
Current: $913.87
Upside: +40.06%
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $745 → $800
Current: $760.98
Upside: +5.13%
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $4.00
Upside: +25.00%
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $1.93
Upside: +314.51%
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $439.86
Upside: +17.08%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $28.34
Upside: +94.07%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $200.88
Upside: +29.43%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $40.45
Upside: -13.47%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $106.68
Upside: +40.61%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $55.75
Upside: -15.70%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $22.82
Upside: +31.46%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $38.30
Upside: +82.77%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.48
Upside: +13.29%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $29.55
Upside: +6,245.18%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $8.00
Upside: +350.00%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $7.63
Upside: +149.02%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.53
Upside: +3,821.57%